Physician profile
Ben Lee
NPI 1376884833
$11,116.43
in general payments reported to CMS, 2019-2025
47 companies · $1,538 in 2025
The $1,538 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,586 · 2020: $1,451 · 2021: $1,479 · 2022: $1,899 · 2023: $1,680 · 2024: $1,485 · 2025: $1,538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,702.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,857.53 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $1,186.19 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,173.58 | 2021-2025 | |
| Pfizer INC. | $1,096.58 | 2019-2025 | |
| Lilly USA, LLC | $991.75 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $586.00 | 2019-2025 | Otezla, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $542.05 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $457.22 | 2019-2025 | Ofev, Stiolto Respimat, Jardiance |
| Glaxosmithkline, LLC. | $410.74 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $369.79 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $252.56 | 2019-2023 | |
| Mylan Specialty L.P. | $250.92 | 2020-2024 | Yupelri |
| Biohaven Pharmaceutical Holding Company Ltd. | $152.28 | 2022 | |
| Abbott Laboratories | $141.21 | 2021-2025 | Freestyle Libre 3 |
| Halozyme INC | $129.67 | 2023 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ben Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.